-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio Q2 FY26 net loss narrows to $1.3 million; revenue is no revenue

PUBT·08/06/2026 20:00:57
Listen to the news
INmune Bio Q2 FY26 net loss narrows to $1.3 million; revenue is no revenue
  • INmune Bio reported a net loss attributable to common stockholders of about USD 1.3 million, narrowing from about USD 24.5 million a year earlier.
  • R&D swung to a benefit of about USD 803,000 from expense of about USD 5.8 million, on recognition of additional Australian R&D tax rebate.
  • G&A was about USD 2.3 million, little changed from a year earlier; cash and cash equivalents were about USD 18.4 million at June 30.
  • Management said MHRA alignment, PIP approval, and commercial-ready manufacturing reduced risk ahead of a planned UK MAA filing for Ebstrocel in RDEB.
  • XPro received FDA Fast Track; Phase 2 MINDFuL showed a statistically significant MRI myelin biomarker effect (p=0.0028) supporting a registrational Phase 2b/3 protocol submission in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061600PRIMZONEFULLFEED9805473) on August 06, 2026, and is solely responsible for the information contained therein.